JP2003516940A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003516940A5 JP2003516940A5 JP2001537971A JP2001537971A JP2003516940A5 JP 2003516940 A5 JP2003516940 A5 JP 2003516940A5 JP 2001537971 A JP2001537971 A JP 2001537971A JP 2001537971 A JP2001537971 A JP 2001537971A JP 2003516940 A5 JP2003516940 A5 JP 2003516940A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- igm
- lymphocyte
- producing
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000781 anti-lymphocytic effect Effects 0.000 description 11
- 210000000628 antibody-producing cell Anatomy 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 102000009410 Chemokine receptor Human genes 0.000 description 3
- 108050000299 Chemokine receptor Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/439,690 | 1999-11-14 | ||
| US43969099A | 1999-11-15 | 1999-11-15 | |
| US09/684,813 | 2000-10-10 | ||
| US09/684,813 US6610834B1 (en) | 1998-11-18 | 2000-10-10 | Human IgM antibodies to chemokine receptors |
| PCT/US2000/031051 WO2001035980A1 (en) | 1999-11-14 | 2000-11-14 | HUMAN IgM ANTIBODIES TO CHEMOKINE RECEPTORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003516940A JP2003516940A (ja) | 2003-05-20 |
| JP2003516940A5 true JP2003516940A5 (enExample) | 2007-12-06 |
Family
ID=27032133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001537971A Pending JP2003516940A (ja) | 1999-11-15 | 2000-11-14 | ケモカイン受容体に対するヒトＩｇＭ抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6610834B1 (enExample) |
| EP (1) | EP1231930B1 (enExample) |
| JP (1) | JP2003516940A (enExample) |
| AT (1) | ATE464909T1 (enExample) |
| AU (1) | AU1599601A (enExample) |
| CA (1) | CA2389851A1 (enExample) |
| DE (1) | DE60044259D1 (enExample) |
| WO (1) | WO2001035980A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030099645A1 (en) * | 2000-10-10 | 2003-05-29 | Lobo Peter Isaac | Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes |
| US20080118522A1 (en) * | 1998-11-18 | 2008-05-22 | Lobo Peter I | Naturally occuring IgM antibodies that bind lymphocytes |
| WO2005108989A2 (en) * | 2004-04-16 | 2005-11-17 | Genentech, Inc. | Assay for antibodies |
| EP1817054A1 (en) * | 2004-12-01 | 2007-08-15 | Peter I. Lobo | Naturally occuring igm antibodies that bind lymphocytes |
| TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
| BRPI0707446A2 (pt) | 2006-02-02 | 2011-05-03 | Allergan Inc | composições e métodos para o tratamento de doença oftálmica |
| TW200817438A (en) * | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
| WO2008019817A1 (en) | 2006-08-17 | 2008-02-21 | F. Hoffmann-La Roche Ag | A conjugate of an antibody against ccr5 and an antifusogenic peptide |
| KR20090052358A (ko) | 2006-09-29 | 2009-05-25 | 에프. 호프만-라 로슈 아게 | Ｃｃｒ5 에 대한 항체 및 이의 용도 |
| CL2008000707A1 (es) * | 2007-03-13 | 2008-09-22 | Hoffmann La Roche | Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion. |
| GB201002238D0 (en) | 2010-02-10 | 2010-03-31 | Affitech As | Antibodies |
| EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| US20210311048A1 (en) * | 2016-02-16 | 2021-10-07 | Celltrend Gmbh | Anti-CXC chemokine receptor antibodies and C-X-C chemokines for the diagnosis of autoimmune disease and graft-versus-host disease |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8605316D0 (en) * | 1986-03-04 | 1986-04-09 | Royal Free Hosp School Med | Immunosuppression |
| US5215913A (en) * | 1987-11-30 | 1993-06-01 | Roger Williams General Hospital | IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use |
| US5606026A (en) * | 1988-03-25 | 1997-02-25 | The Institute For Human Genetics And Biochemistry | Natural human IgM antibodies immunoreactive with the Tat protein of HIV-1 |
| EP0672142B1 (en) * | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5959085A (en) * | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| US5961976A (en) * | 1996-06-03 | 1999-10-05 | United Biomedical, Inc. | Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV |
| WO1997049424A1 (en) * | 1996-06-25 | 1997-12-31 | The Trustees Of The University Of Pennsylvania | Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same |
| US5994515A (en) * | 1996-06-25 | 1999-11-30 | Trustees Of The University Of Pennsylvania | Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same |
| US6057102A (en) * | 1996-08-08 | 2000-05-02 | The Aaron Diamond Aids Research Center | HIV coreceptor mutants |
| US6100387A (en) | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
| US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| JP2000229997A (ja) * | 1999-02-10 | 2000-08-22 | Nissui Pharm Co Ltd | 環状ペプチド及びエイズワクチン |
-
2000
- 2000-10-10 US US09/684,813 patent/US6610834B1/en not_active Expired - Fee Related
- 2000-11-14 AT AT00978542T patent/ATE464909T1/de not_active IP Right Cessation
- 2000-11-14 AU AU15996/01A patent/AU1599601A/en not_active Abandoned
- 2000-11-14 DE DE60044259T patent/DE60044259D1/de not_active Expired - Lifetime
- 2000-11-14 CA CA002389851A patent/CA2389851A1/en not_active Abandoned
- 2000-11-14 EP EP00978542A patent/EP1231930B1/en not_active Expired - Lifetime
- 2000-11-14 WO PCT/US2000/031051 patent/WO2001035980A1/en not_active Ceased
- 2000-11-14 JP JP2001537971A patent/JP2003516940A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heinonen et al. | Infant immune response to respiratory viral infections | |
| Kiyono et al. | NALT-versus Peyer's-patch-mediated mucosal immunity | |
| Hagiwara et al. | Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue | |
| JP2003516940A5 (enExample) | ||
| Iijima et al. | Alteration of Interleukin 4 Production Results in the Inhibition of T Helper Type 2 Cell–Dominated Inflammatory Bowel Disease in T Cell Receptor α Chain–Deficient Mice | |
| Yanagita et al. | Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production | |
| CN1318589C (zh) | 制备哺乳动物细胞激动素合成抑制因子的方法 | |
| Patella et al. | Endogenous superallergen protein Fv induces IL-4 secretion from human FcεRI+ cells through interaction with the VH3 region of IgE | |
| Dahlgren et al. | Type I interferons promote germinal centers through B cell intrinsic signaling and dendritic cell dependent Th1 and Tfh cell lineages | |
| Drewe et al. | Clinically useful monoclonal antibodies in treatment | |
| Schaefer et al. | The biophysical principles underpinning muco-trapping functions of antibodies | |
| JP2010241819A (ja) | ヒト−マウスキメラ抗呼吸シンシチアルウイルス抗体 | |
| EP0387095A1 (en) | Pharmaceutical product for the treatment of immunoregulatory disorders | |
| Schopf et al. | Interleukin-4-dependent immunoglobulin G1 isotype switch in the presence of a polarized antigen-specific Th1-cell response to the trypanosome variant surface glycoprotein | |
| TW201808998A (zh) | 以cd4抗體於穩定接受haart治療的患者進行hiv感染的治療和持續性的病毒緩解 | |
| Agnello et al. | Intrarectal immunization and IgA antibody-secreting cell homing to the small intestine | |
| JP2008013573A (ja) | 内毒素または超抗原に誘導された毒性を治療するインターロイキン−１０類似体またはアンタゴニストの使用 | |
| Markine-Goriaynoff et al. | Distinct requirements for IL-6 in polyclonal and specific Ig production induced by microorganisms | |
| LI et al. | Polyclonal B cell activation of IgG2a and IgG2b production by infection of mice with lactate dehydrogenase-elevating virus is partly dependent on CD4+ lymphocytes | |
| JP2007533622A (ja) | ヒトサイトカインの生物活性をブロッキングするヒト抗体を高収率で産生する方法 | |
| Horohov | Equine T-cell cytokines: protection and pathology | |
| Yoshino | Effect of a monoclonal antibody against interleukin‐4 on collagen‐induced arthritis in mice | |
| Kullberg et al. | T cell-derived IL-3 induces the production of IL-4 by non-B, non-T cells to amplify the Th2-cytokine response to a non-parasite antigen in Schistosoma mansoni-infected mice | |
| Goldman et al. | Hyperactivity of donor B cells after neonatal induction of lymphoid chimerism in mice | |
| Paar et al. | Immunotherapy of CMV infections |